Market Cap 395.31B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.07
Forward PE 21.35
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 5,243,800
Avg Vol 5,612,076
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 45%
Beta 0.36
Analysts Strong Sell
Price Target $245.40

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 18 at 6:49 AM
$SLS the VIALE-M trial for AML Maintenance in first remission was Direct existential threat to Gps. - and it Failed - $ABBV Spent nearly a billion dollars on the VIALE-M, VIALE-T and VERONA Phase 3 Trials, planning to open a very size-able Maintenance market - and they failed. And VIALE-A for front line AML patients ineligible for Intensive chemo, results were never reproduced and 23% of the Aza VEN Patients DIED from Taking AzaVEN. AZA VEN is not an effective AML Remission Maintenance treatment. https://www.onclive.com/view/verona-trial-misses-primary-end-point-of-os-benefit-with-azacitidine-venetoclax-in-higher-risk-mds
0 · Reply
RunnerSignals
RunnerSignals Dec. 18 at 4:09 AM
Unusual options heat popping on ​$META $COST $ABBV $CRM $SNOW worth a closer look before the next move. https://stocksrunner.com/news/2025-12-17-unusual-stock-options-activity-today
0 · Reply
TalkMarkets
TalkMarkets Dec. 18 at 12:11 AM
The 10 Best Performing #Dividend Aristocrats In The Past 10 Years $CAT $NUE $WMT $CTAS $ABBV https://talkmarkets.com/content/stocks--equities/the-10-best-performing-dividend-aristocrats-in-the-past-10-years?post=545368
0 · Reply
Quantumup
Quantumup Dec. 17 at 9:15 PM
Mizuho🏁 $SYRE Outperform/$53 $JNJ $ABBV Mizuho said: We are initiating coverage of Spyre Therapeutics with an Outperform rating and $53 PT, as we see SYRE's HLE mAb pipeline (SPY001, SPY002 and SPY003) as positioned to play a significant role in inflammatory bowel disease. While we believe that each has opportunity to establish best-in-class monotherapy profiles in 2026, in our view the most compelling opportunity lies in SYRE's ability to evaluate novel combinations. Here, we believe combination data in 2027 could position SYRE with best-in-class/first-in-class dual pathway strategies, an approach validated by preclinical data, translational data, early clinical data, as well as competitive Pharma development. Altogether, we project $1.7B in risk-adjusted 2035 WW sales, and expect positive Phase II monotherapy data in 2026, followed by combination data in 2027 to drive outperformance.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 5:44 PM
$SLS Recap: Phase 3 Final Results are Now Due -- Expected THIS MONTH. 1. ) BAT for Control ARM Patients Failed 3 Large / Expensive Phase 3 Trials Conducted by $ABBV due to toxicity -esp in the maintenance setting. 2.) We have 3 Dr's On the Record stating, MOS for Control Patients is Dismal / Extremely Poor / not Durable -just 5-7 months 6-8 months. 3. Idmc unblinded actual P3 MOS and Immune Response Data that confirms Gps Phase 3 Patient MOS is LONGER than the GPS Phase 2 21 Month MOS. All the facts are knowable: its why we now have 155 Institutional Funds Invested, up from 39, Since the IDMC unblinded Interim Analysis data - and the Share price is up 150%, and the Market Cap is up 400% and the cash on hand was only 13M is now $74M --- Phase 3 Final Results are Now Due -- Incoming THIS MONTH.
0 · Reply
rpc630
rpc630 Dec. 17 at 5:37 PM
$SLS $ABBV Deserves A Reposts!! 👏
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 5:27 PM
$SLS @Juhanialainen an interesting observation, three Dr's who treat actual Phase 3 trial patients in the control arm, are on record* stating the Best Available Treatment, BAT is toxic in this second remission maintenance setting - and "MOS is not durable, extremely poor and dismal, just 6-8 months." - meanwhile BAT/ AzaVEN has recently failed 3 large Phase 3 trials conducted by $ABBV ... and based on known data - Idmc unblinded actual Phase 3 Interim analysis data, -- Gps Phase 3 Patient MOS will be Longer than the Statistically Significant Phase 2, 21 month MOS result. * all the transcripts/ webinars are available. Dr. Jamy Dr. Levy Dr. Tsirigotis - have all said the same thing - MOS with Aza VEN - which is the BAT - is Dismal.
0 · Reply
MessAndGetHorns
MessAndGetHorns Dec. 17 at 2:51 PM
$ESTA Mizhuho 85 to 90. Buyout from $JNJ or $ABBV coming with a PT of 150. Everyone wants the breast implants! GLP-1s are leaving more and more women with less breast volume and this is what they are spending their reduced grocery budgets on! $SPY $QQQ
0 · Reply
Quantumup
Quantumup Dec. 17 at 2:21 PM
RBC Capital reiterated $ONC Outperform-$408 and said, In-House Capabilities Can Drive Sustainable Near- and Long-Term Innovation $LLY $ABBV $AZN $VSTM BGNE ZLAB RBC Said: Yesterday we had the opportunity to take ONC mgmt on the road, with investor conversations focusing largely on the sustainability of ONC's development engine, as well as near-term competitive threats. We felt mgmt was confident that the company had built a true moat that enabled them to execute quickly and bring best-in-class molecules to the clinic and market — exemplified by Brukinsa, sonrotoclax, and '16673, which together round out their leadership in heme-onc with potential to offer treatment regimen for all slices of the market. We see reason to believe they can extend this strategy to solid tumors — which could constitute significant upside potential both to our and cons. ests. — and with the recent pullback in shares, we would be buyers into 2026 and data catalysts across both liquid and solid tumors.
0 · Reply
Quantumup
Quantumup Dec. 17 at 1:34 PM
Guggenheim⬆️ 2026 Top Pick $TENX's PT to $25 from $14, and reiterated at a Buy rating. $MRK $ABBV $TECX $LLY AZN NVS Here what Guggenheim had to say 'Today' and also on 'August 14': https://x.com/Quantumup1/status/2001281778309292543?s=20
0 · Reply
Latest News on ABBV
AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 7 days ago

AbbVie: Unique Mix Of Growth And Value


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 18 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 5 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 5 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 5 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 6 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 6 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 6 weeks ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 6 weeks ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 6 weeks ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 7 weeks ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 7 weeks ago

AbbVie: Deep Discount Before Earnings


Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 18 at 6:49 AM
$SLS the VIALE-M trial for AML Maintenance in first remission was Direct existential threat to Gps. - and it Failed - $ABBV Spent nearly a billion dollars on the VIALE-M, VIALE-T and VERONA Phase 3 Trials, planning to open a very size-able Maintenance market - and they failed. And VIALE-A for front line AML patients ineligible for Intensive chemo, results were never reproduced and 23% of the Aza VEN Patients DIED from Taking AzaVEN. AZA VEN is not an effective AML Remission Maintenance treatment. https://www.onclive.com/view/verona-trial-misses-primary-end-point-of-os-benefit-with-azacitidine-venetoclax-in-higher-risk-mds
0 · Reply
RunnerSignals
RunnerSignals Dec. 18 at 4:09 AM
Unusual options heat popping on ​$META $COST $ABBV $CRM $SNOW worth a closer look before the next move. https://stocksrunner.com/news/2025-12-17-unusual-stock-options-activity-today
0 · Reply
TalkMarkets
TalkMarkets Dec. 18 at 12:11 AM
The 10 Best Performing #Dividend Aristocrats In The Past 10 Years $CAT $NUE $WMT $CTAS $ABBV https://talkmarkets.com/content/stocks--equities/the-10-best-performing-dividend-aristocrats-in-the-past-10-years?post=545368
0 · Reply
Quantumup
Quantumup Dec. 17 at 9:15 PM
Mizuho🏁 $SYRE Outperform/$53 $JNJ $ABBV Mizuho said: We are initiating coverage of Spyre Therapeutics with an Outperform rating and $53 PT, as we see SYRE's HLE mAb pipeline (SPY001, SPY002 and SPY003) as positioned to play a significant role in inflammatory bowel disease. While we believe that each has opportunity to establish best-in-class monotherapy profiles in 2026, in our view the most compelling opportunity lies in SYRE's ability to evaluate novel combinations. Here, we believe combination data in 2027 could position SYRE with best-in-class/first-in-class dual pathway strategies, an approach validated by preclinical data, translational data, early clinical data, as well as competitive Pharma development. Altogether, we project $1.7B in risk-adjusted 2035 WW sales, and expect positive Phase II monotherapy data in 2026, followed by combination data in 2027 to drive outperformance.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 5:44 PM
$SLS Recap: Phase 3 Final Results are Now Due -- Expected THIS MONTH. 1. ) BAT for Control ARM Patients Failed 3 Large / Expensive Phase 3 Trials Conducted by $ABBV due to toxicity -esp in the maintenance setting. 2.) We have 3 Dr's On the Record stating, MOS for Control Patients is Dismal / Extremely Poor / not Durable -just 5-7 months 6-8 months. 3. Idmc unblinded actual P3 MOS and Immune Response Data that confirms Gps Phase 3 Patient MOS is LONGER than the GPS Phase 2 21 Month MOS. All the facts are knowable: its why we now have 155 Institutional Funds Invested, up from 39, Since the IDMC unblinded Interim Analysis data - and the Share price is up 150%, and the Market Cap is up 400% and the cash on hand was only 13M is now $74M --- Phase 3 Final Results are Now Due -- Incoming THIS MONTH.
0 · Reply
rpc630
rpc630 Dec. 17 at 5:37 PM
$SLS $ABBV Deserves A Reposts!! 👏
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 5:27 PM
$SLS @Juhanialainen an interesting observation, three Dr's who treat actual Phase 3 trial patients in the control arm, are on record* stating the Best Available Treatment, BAT is toxic in this second remission maintenance setting - and "MOS is not durable, extremely poor and dismal, just 6-8 months." - meanwhile BAT/ AzaVEN has recently failed 3 large Phase 3 trials conducted by $ABBV ... and based on known data - Idmc unblinded actual Phase 3 Interim analysis data, -- Gps Phase 3 Patient MOS will be Longer than the Statistically Significant Phase 2, 21 month MOS result. * all the transcripts/ webinars are available. Dr. Jamy Dr. Levy Dr. Tsirigotis - have all said the same thing - MOS with Aza VEN - which is the BAT - is Dismal.
0 · Reply
MessAndGetHorns
MessAndGetHorns Dec. 17 at 2:51 PM
$ESTA Mizhuho 85 to 90. Buyout from $JNJ or $ABBV coming with a PT of 150. Everyone wants the breast implants! GLP-1s are leaving more and more women with less breast volume and this is what they are spending their reduced grocery budgets on! $SPY $QQQ
0 · Reply
Quantumup
Quantumup Dec. 17 at 2:21 PM
RBC Capital reiterated $ONC Outperform-$408 and said, In-House Capabilities Can Drive Sustainable Near- and Long-Term Innovation $LLY $ABBV $AZN $VSTM BGNE ZLAB RBC Said: Yesterday we had the opportunity to take ONC mgmt on the road, with investor conversations focusing largely on the sustainability of ONC's development engine, as well as near-term competitive threats. We felt mgmt was confident that the company had built a true moat that enabled them to execute quickly and bring best-in-class molecules to the clinic and market — exemplified by Brukinsa, sonrotoclax, and '16673, which together round out their leadership in heme-onc with potential to offer treatment regimen for all slices of the market. We see reason to believe they can extend this strategy to solid tumors — which could constitute significant upside potential both to our and cons. ests. — and with the recent pullback in shares, we would be buyers into 2026 and data catalysts across both liquid and solid tumors.
0 · Reply
Quantumup
Quantumup Dec. 17 at 1:34 PM
Guggenheim⬆️ 2026 Top Pick $TENX's PT to $25 from $14, and reiterated at a Buy rating. $MRK $ABBV $TECX $LLY AZN NVS Here what Guggenheim had to say 'Today' and also on 'August 14': https://x.com/Quantumup1/status/2001281778309292543?s=20
0 · Reply
Longbuy1
Longbuy1 Dec. 17 at 1:26 PM
$SLS whose gonna buy us $PFE or $ABBV . Two best in class AML treatments only 10 bil fire sale.
0 · Reply
RodTownsend
RodTownsend Dec. 17 at 9:33 AM
$ABBV AbbVie pipeline depth and cash flow profile keep this one attractive for defensive growth setups
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 5:46 AM
$SLS $ABBV @sninvestor What an Obvious Lying Tool. Struggled??? you tool. 3 Large Phase 3 Trials were Terminated - by $ABBV - these were registrational Trials, maybe you short bus tools don't understand what that means. it did fail broadly - AML is AML - its the same BIOLOGY. - in a very Similar Setting - VIALE-M was AML CR1 Ineligible for Transplant - REGAL is AML CR2 Ineligible for Transplant - AS CLOSE a comp there is. and Aza+VEN Killed 23% of the Patients in the VIALE-A trial. . . . https://cdn.clinicaltrials.gov/large-docs/20/NCT04102020/SAP_001.pdf SAP for VIALE-M These are some of the Ven + Aza VIALE-A Side Effects
0 · Reply
sninvestor
sninvestor Dec. 17 at 4:29 AM
$ABBV $SLS This mixes real facts with conclusions that don’t follow. Yes, Aza+VEN has struggled in some maintenance and post-transplant settings — largely due to toxicity and patient selection — but that does not mean it “failed broadly” or that those outcomes automatically prove GPS efficacy in REGAL. VIALE-M (CR1), VIALE-T (post-transplant), and VERONA were different populations, different biology, and different trial designs than REGAL’s CR2 maintenance setting. More importantly, REGAL is an OS-driven, blinded Phase 3 trial. You can’t infer arm-specific benefit or claim GPS is “doing all the heavy lifting” without seeing the hazard ratio and survival curves. Aza+VEN’s limitations are relevant context, but they don’t substitute for REGAL data. If GPS wins, it will be because the Phase 3 OS data show superiority — not because other trials failed elsewhere.
4 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 17 at 4:18 AM
$SLS Just want to be clear, does Everyone Understand, Aza+VEN - the Best Available Treatment (BAT) for the REGAL Phase 3 CONTROL ARM Patients - Recently FAILED 3 Large Phase 3 Trials? - VERONA - MDS/AML Precursor Trial Failed - VIALE-T - AML Post Transplant Maintenance P3 FAILED - VIALE-M - AML First Remission CR1 Maintenance P3 FAILED - all due toxicity - Tracking w Several Dr's who treat actual P3 RGAL Patients. Including the Dr. Levy - Dir. of Hematological Research at BAYLOR Med. https://viavid.webcasts.com/viewer/event.jsp?ei=1704094&tp_key=e7faa24f6d - the VIALE-M CR1 Maintenance trial (TERMINATED NCT Date 08/2025) was an Existential Threat to GPS, currently about to Report Phase 3 Results for CR2 Maintenance. -- Aza+VEN Failing 3 Phase 3 Trials, including 2 AML Maintenance Trials - is a pretty big deal - Cost $ABBV near a billion in R&D - and Proves its GPS doing all the heavy lifting Keeping the REGAL P3 patients Alive way longer than anyone imagined. //
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:00 AM
$ABBV: Current market context shows a bearish sentiment with the last close at $223.26 and an RSI of 37.06, indicating potential oversold conditions. The price is below the MA30 ($226.65) and MA50 ($227.08), reinforcing a bearish bias. The 60D high of $244.81 and low of $211.69 suggests a range-bound market, providing key levels for our trade. Actionable Trade Alert: - Suggested Entry: $222.50 (slightly below last close) - Stop Loss: $218.00 (below the 60D low) - Take Profit Targets: 1. $230.00 (3.4% ROI) 2. $236.00 (5.7% ROI) 3. $261.00 (17% ROI) With the ATR at 4.42, these targets provide significant upside potential while managing risk effectively. Monitor RSI for signs of reversal as we approach targets. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 7:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $220.00 Put · DEC 26, 2025 Exp Entry Price: $1.99 - $2.17 Exit Price Target: $4.00 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 7:38 PM
$ABBV Source of funds, POS
0 · Reply
Godreal1
Godreal1 Dec. 16 at 6:33 PM
$ABBV this stock is a joke been droppping all day ! And I know it’s had great news for the last two week barely move smh
0 · Reply
Czreri1
Czreri1 Dec. 16 at 5:55 PM
$ABBV this stock is a joke. Literally a prime example of manipulation.
0 · Reply
RodTownsend
RodTownsend Dec. 16 at 5:44 PM
$ABBV 🔥
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 4:50 PM
$SLS $ Meetings with $PFE, $ABBV is going to step up. Bidding war upcoming for BO.
1 · Reply